MARKET

HALO

HALO

Halozyme Thrp
NASDAQ
71.53
-0.07
-0.10%
After Hours: 71.86 +0.33 +0.46% 19:52 06/05 EDT
OPEN
71.73
PREV CLOSE
71.60
HIGH
72.25
LOW
70.71
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
82.22
52 WEEK LOW
51.06
MARKET CAP
8.48B
P/E (TTM)
25.73
1D
5D
1M
3M
1Y
5Y
1D
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation
Simply Wall St · 1d ago
What Halozyme Therapeutics (HALO)'s New ENHANZE Partner Data and Analyst Support Means For Shareholders
Simply Wall St · 2d ago
Halozyme publishes 2025 greenhouse gas accounting summary report
PUBT · 2d ago
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
Barchart · 3d ago
Halozyme director Bernadette Connaughton sells 1,625 shares worth $107,591.25
PUBT · 3d ago
Weekly Report: what happened at HALO last week (0525-0529)?
Weekly Report · 5d ago
Averin Capital Acquisition names Akiko Moni Miyashita to board
PUBT · 05/29 20:32
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans
NASDAQ · 05/27 12:48
More
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Webull offers Halozyme Therapeutics, Inc. stock information, including NASDAQ: HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.